Wearable devices can identify, differentiate, and predict flare-ups, or the worsening of symptoms and inflammation, in inflammatory bowel disease (IBD), Mount Sinai researchers have shown in a ...
Approval was based on results of the VIVID-1 study, which found that Omvoh demonstrated significant clinical remission and ...
The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second interleukin-23p19 specific inhibitor approved for both major types of inflammatory ...
CARLSBAD, CA - Palisade Bio, Inc. (NASDAQ: PALI), a clinical-stage biopharmaceutical company with a market capitalization of ...
(RTTNews) - Palisade Bio, Inc. (PALI), Thursday announced a preliminary data from five planned Single Ascending Dose cohorts, showing that PALI-2018 was well-tolerated among doses ranging from 15 mg ...
Company on track to report topline data in first half of 2025Positive preliminary data from all five single ascending dose (SAD) cohorts ranging ...
Eli Lilly and Company LLY announced that the FDA has granted approval to its drug, Omvoh (mirikizumab), for its second ...
Omvoh's approval as a treatment for Crohn's disease was based on results from a study in which 53% of patients treated with the drug achieved clinical remission, and 46% of patients had visible ...
Financial Highlights for the Second Quarter of Fiscal 2025 Biomerica continued to deliver improved financial performance, demonstrating revenue growth, disciplined cost management, and progress toward ...
The sequence of biologic treatments in patients with inflammatory bowel disease significantly affects their risk of adverse ...
The CEO of Spyre, Cameron Turtle, emphasized the company's progress in 2024, including entering first-in-human studies with ...
A study published in the Journal of Inflammation Research reveals that cannabidiol (CBD) has therapeutic potential for ...